Tarix, Unigene deal

Tarix and Unigene partnered to develop an oral formulation of Tarix's TXA127 using Unigene's Peptelligence drug delivery technology. In September, Tarix exercised an option to license exclusive, worldwide rights to the Peptelligence for use with angiotensin I-VII and its functional equivalents, analogs and derivatives. Angiotensin is the pharmaceutical ingredient in TXA127, a peptide that stimulates early hematopoietic precursor cells in the bone marrow. Unigene is eligible for an undisclosed percentage of sales of products as well as an undisclosed percentage of upfront and milestone payments, and royalties from a third-party licensing deal (see BioCentury, Sept. 24). ...